Michael Barbella, Managing Editor05.22.24
SHL Telemedicine Ltd. is sharing promising results of an Imperial College (London)-sponsored study showing its SmartHeart 12-lead ECG technology can significantly reduce hospital readmissions and emergency department visits for post-myocardial infarction (heart attack) patients at home.
Key findings from the randomized TELE-ACS trial included:
"The results of this pivotal study and publication in JACC, serve as a resounding vote of confidence in SHL and our SmartHeart platform as a transformative technology for cardiac care and telemedicine as a whole," SHL Telemedicine CEO Erez Nachtomy said. "These clinical results are an endorsement that propels us forward in our mission to redefine patient care, demonstrating the tangible benefits and efficiency of our telemedicine solutions on a global scale."
SHL Telemedicine develops and markets personal telemedicine systems and the provision of medical call center services, with a focus on cardiovascular and related diseases, to end users and to the healthcare community. SHL Telemedicine offers its services and personal telemedicine devices to subscribers utilizing telephonic and Internet communication technology. SHL is listed on the SIX Swiss Exchange and on the Nasdaq Stock Exchange.
Key findings from the randomized TELE-ACS trial included:
- A 76% reduction in the likelihood of hospital readmission within six months for patients using telemedicine.
- A 41% decrease in likely emergency department (ED) visits compared to standard care recipients.
- Significant reductions in unplanned coronary revascularizations.
- Notable decreases in patient-reported symptoms (chest pain, breathlessness, dizziness).
"The results of this pivotal study and publication in JACC, serve as a resounding vote of confidence in SHL and our SmartHeart platform as a transformative technology for cardiac care and telemedicine as a whole," SHL Telemedicine CEO Erez Nachtomy said. "These clinical results are an endorsement that propels us forward in our mission to redefine patient care, demonstrating the tangible benefits and efficiency of our telemedicine solutions on a global scale."
SHL Telemedicine develops and markets personal telemedicine systems and the provision of medical call center services, with a focus on cardiovascular and related diseases, to end users and to the healthcare community. SHL Telemedicine offers its services and personal telemedicine devices to subscribers utilizing telephonic and Internet communication technology. SHL is listed on the SIX Swiss Exchange and on the Nasdaq Stock Exchange.